TGFβ1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis

Oral Oncology

Volumn 46, Issue 5, 2010, Pages 369-372

  Lundberg, Marie ^a   Saarilahti, Kauko ^a   Mäkitie, Antti A ^a   Mattila, Petri S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chemotherapy; Complications; Head and neck cancer; Mucous membrane; Neoplasm; Radiotherapy; Survival; Transforming growth factor beta

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA; GEFITINIB; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; ORAL MUCOSAL DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INJURY; SQUAMOUS CELL CARCINOMA; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77950860609     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.02.012     Document Type: Article

References (21)

1. Pignon J.P., le Maitre A., Maillard E., and Bourhis J. MACH-NC collaborative G. Radiother Oncol 92 1 (2009) 4-14
2. Herrstedt J. Prevention and management of mucositis in patients with cancer. Int J Antimicrob Agents 16 2 (2000) 161-163
3. Treister N., and Sonis S. Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg 15 2 (2007) 123-129
4. Trotti A., Bellm L.A., Epstein J.B., Frame D., Fuchs H.J., Gwede C.K., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66 3 (2003) 253-262
5. Vissink A., Jansma J., Spijkervet F.K., Burlage F.R., and Coppes R.P. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14 3 (2003) 199-212
6. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 47 1 (2000) 1-12
7. Archambeau J.O., Pezner R., and Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys 31 5 (1995) 1171-1185
8. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med 342 18 (2000) 1350-1358
9. Flanders K.C., and Burmester J.K. Medical applications of transforming growth factor-beta. Clin Med Res 1 1 (2003) 13-20
10. Sonis S.T., Van Vugt A.G., Brien J.P., Muska A.D., Bruskin A.M., Rose A., et al. Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 33 1 (1997) 47-54
11. Wymenga A.N., van der Graaf W.T., Hofstra L.S., Spijkervet F.K., Timens W., Timmer-Bosscha H., et al. Phase I study of transforming growth factor-beta 3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res 5 6 (1999) 1363-1368
12. Foncuberta M.C., Cagnoni P.J., Brandts C.H., Mandanas R., Fields K., Derigs H.G., et al. Investigators in TGF/OM study protocols. Topical transforming growth factor-[beta]3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother 24 4 (2001) 384-388
13. van't Land B., Meijer H.P., Frerichs J., Koetsier M., Jager D., Smeets R.L., et al. Transforming growth factor-beta 2 protects the small intestine during methotrexate treatment in rats possibly by reducing stem cell cycling. Br J Cancer 87 1 (2002) 113-118
14. Harsha W.T.F., Kalandarova E., McNutt P., Irwin R., and Noel J. Nutritional supplementation with transforming growth factor-[beta], glutamine, and short chain fatty acids minimizes methotrexate-induced injury. J Pediatr Gastroenterol Nutr 42 1 (2006) 53-58
15. Dunning A.M., Ellis P.D., McBride S., Kirschenlohr H.L., Healey C.S., Kemp P.R., et al. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63 10 (2003) 2610-2615
16. Lundberg M., Pajusto M., Koskinen W.J., Makitie A.A., Aaltonen L.M., and Mattila P.S. Association between transforming growth factor beta1 genetic polymorphism and response to chemoradiotherapy in head and neck squamous cell cancer. Head Neck 31 5 (2009) 664-672
17. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31 5 (1995) 1341-1346
18. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 4 4 (2004) 277-284
19. Fowler J.F., and Lindstrom M.J. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23 2 (1992) 457-467
20. Eisbruch A. Intensity-modulated radiation therapy in the treatment of head and neck cancer. Nat Clin Pract Oncol 2 1 (2005) 34-39
21. Saarilahti K., Kouri M., Collan J., Hamalainen T., Atula T., Joensuu H., et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 74 3 (2005) 251-258